Szofia Szentpeteri1, Levente Schmidt2, Laszlo Restar3, Gabor Csaki4, Gyorgy Szabo5, Mihaly Vaszilko6. 1. Resident, Department of Oro-Maxillofacial Surgery and Stomatology, Semmelweis University, Budapest, Hungary. Electronic address: szentpeteriszofia@gmail.com. 2. Clinical Doctor, Department of Oro-Maxillofacial Surgery and Dentoalveolar Surgery, Military Hospital-State Health Centre, Budapest, Hungary. 3. Clinical Doctor, Department of Oro-Maxillofacial Surgery and Stomatology, Semmelweis University, Budapest, Hungary. 4. Vice-Department Head, Department of Oro-Maxillofacial Surgery and Dentoalveolar Surgery, Military Hospital-State Health Centre, Budapest, Hungary. 5. Professor, Department of Oro-Maxillofacial Surgery and Stomatology, Semmelweis University, Budapest, Hungary. 6. Vice-Department Head, Department of Oro-Maxillofacial Surgery and Stomatology, Semmelweis University, Budapest, Hungary.
Abstract
PURPOSE: We examined the effect of the membranous form of platelet-rich fibrin (PRF) on patients with medication-related osteonecrosis of the jaw. MATERIALS AND METHODS: Our study included patients who underwent an operation because of second- or third-stage osteonecrosis of the jaw induced by antiresorptive therapy. The diagnosis of medication-related osteonecrosis of the jaw was based on the 2009 and 2014 recommendations of the American Association of Oral and Maxillofacial Surgeons. On the basis of the duration of treatment, we divided our patients into 2 groups. Patients in the first group (Gr1) underwent traditional surgical therapy between 2009 and 2014, whereas patients in the second group (Gr2) underwent PRF membrane-supplemented operations between 2015 and 2017. Outcomes were assessed based on patient recovery, stage improvement, and relapse rate. The follow-up period was a minimum of 1 year. RESULTS: Our study included 101 patients: 73 in Gr1 and 28 in Gr2. The results in Gr2 were significantly better than those in Gr1: recovery (P = .022), stage improvement (P = .005), and relapse rate (P < .001). CONCLUSIONS: In Gr2, significantly better results were achieved in terms of stage improvement, recovery, and relapse rate than in Gr1.
PURPOSE: We examined the effect of the membranous form of platelet-rich fibrin (PRF) on patients with medication-related osteonecrosis of the jaw. MATERIALS AND METHODS: Our study included patients who underwent an operation because of second- or third-stage osteonecrosis of the jaw induced by antiresorptive therapy. The diagnosis of medication-related osteonecrosis of the jaw was based on the 2009 and 2014 recommendations of the American Association of Oral and Maxillofacial Surgeons. On the basis of the duration of treatment, we divided our patients into 2 groups. Patients in the first group (Gr1) underwent traditional surgical therapy between 2009 and 2014, whereas patients in the second group (Gr2) underwent PRF membrane-supplemented operations between 2015 and 2017. Outcomes were assessed based on patient recovery, stage improvement, and relapse rate. The follow-up period was a minimum of 1 year. RESULTS: Our study included 101 patients: 73 in Gr1 and 28 in Gr2. The results in Gr2 were significantly better than those in Gr1: recovery (P = .022), stage improvement (P = .005), and relapse rate (P < .001). CONCLUSIONS: In Gr2, significantly better results were achieved in terms of stage improvement, recovery, and relapse rate than in Gr1.